treosulfan has been researched along with Bone Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forsyth, S; Michelagnoli, M; Whelan, J | 1 |
| Elverfeldt, DV; Juettner, E; Kontny, U; Reichardt, W; Uhl, M | 1 |
| Boos, J; Bremer, A; Dirksen, U; Jürgens, H; Lanvers-Kaminsky, C | 1 |
1 trial(s) available for treosulfan and Bone Cancer
| Article | Year |
|---|---|
A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Sarcoma, Ewing; Survival Rate | 2015 |
2 other study(ies) available for treosulfan and Bone Cancer
| Article | Year |
|---|---|
Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, SCID; Prognosis; Sarcoma, Ewing; Treatment Outcome; Whole Body Imaging | 2009 |
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Survival; Humans; Leukemia; Neuroblastoma; Osteosarcoma; Sarcoma, Ewing; Tumor Cells, Cultured | 2006 |